Literature DB >> 21720998

Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment?

Gabriella Ferrandina1, Marco Petrillo, Gennaro Restaino, Vittoria Rufini, Gabriella Macchia, Arnaldo Carbone, Gian Franco Zannoni, Alessandro Lucidi, Giorgia D'Angelo, Giovanni Scambia.   

Abstract

BACKGROUND: The goal of this study was to prospectively analyze the diagnostic performances of magnetic resonance imaging (MRI) and positron emission tomography (PET)/computed tomography (CT) in predicting pathologically assessed residual disease in a large, single-institution series of locally advanced cervical cancer (LACC) patients triaged to neoadjuvant treatments followed by radical surgery.
METHODS: Between April 2007 and March 2010, 96 patients with histologically documented cervical cancer (any histology) and FIGO stage IB2-IVA were enrolled. MRI and PET/CT were recommended to be performed within 4-6 weeks from the end of treatment, and histology was the reference standard. Sensitivity, specificity, and accuracy were compared using the McNemar test.
RESULTS: For residual disease in the cervix, sensitivity was higher for MRI than for PET/CT (86.1% vs 63.1%; P = .002), while specificity was significantly higher for PET/CT compared with MRI (P = .002). There was no difference in accuracy values between the 2 imaging modalities. For MRI analysis of lymph node groups, sensitivity, specificity, and accuracy were 35.7%, 95.9%, and 88.0%, respectively. Conversely, sensitivity, specificity, and accuracy for PET/CT were 28.6%, 97.8%, and 88.7%, respectively. Absence of follicular structures replaced by prevalent sclerosis and/or sinus histiocytosis was the most frequently documented morphological pattern in false-positive cases.
CONCLUSION: Neither MRI nor PET/CT accurately detected residual disease in LACC patients triaged to radical surgery after neoadjuvant treatment, disallowing the option of avoiding or modulating completion surgery.
Copyright © 2011 American Cancer Society.

Entities:  

Mesh:

Year:  2011        PMID: 21720998     DOI: 10.1002/cncr.26317

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study.

Authors:  Vittoria Rufini; Angela Collarino; Maria Lucia Calcagni; Guido Maria Meduri; Valentina Fuoco; Tina Pasciuto; Antonia Carla Testa; Gabriella Ferrandina; Maria Antonietta Gambacorta; Maura Campitelli; Benedetta Gui; Gianfranco Zannoni; Riccardo Manfredi; Giovanni Scambia; Alessandro Giordano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-14       Impact factor: 9.236

2.  Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer.

Authors:  Gaiane M Rauch; Harmeet Kaur; Haesun Choi; Randy D Ernst; Ann H Klopp; Piyaporn Boonsirikamchai; Shannon N Westin; Leonardo P Marcal
Journal:  Radiographics       Date:  2014 Jul-Aug       Impact factor: 5.333

3.  Comparison of positron emission tomography/computed tomography and magnetic resonance imaging for posttherapy evaluation in patients with advanced cervical cancer receiving definitive concurrent chemoradiotherapy.

Authors:  Tzu-Pei Su; Gigin Lin; Yu-Ting Huang; Feng-Yuan Liu; Chun-Chieh Wang; Angel Chao; Hung-Hsueh Chou; Tzu-Chen Yen; Chyong-Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-20       Impact factor: 9.236

4.  Prognostic value of post-treatment ¹⁸F-fluorodeoxyglucose positron emission tomography in uterine cervical cancer patients treated with radiotherapy: a systematic review and meta-analysis.

Authors:  Yeon Joo Kim; Sangwon Han; Young Seok Kim; Joo Hyun Nam
Journal:  J Gynecol Oncol       Date:  2019-09       Impact factor: 4.401

5.  A prospective study of the value of pre- and post-treatment magnetic resonance imaging examinations for advanced cervical cancer.

Authors:  Csaba Csutak; Claudia Ordeanu; Viorica Magdalena Nagy; Diana Cristina Pop; Sorana Daniela Bolboaca; Radu Badea; Liliana Chiorean; Sorin Marian Dudea
Journal:  Clujul Med       Date:  2016-07-28

6.  The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer.

Authors:  Simona Leonardi; Marianna Buttarelli; Ilaria De Stefano; Gabriella Ferrandina; Marco Petrillo; Gabriele Babini; Giovanni Scambia; Carmela Marino; Mariateresa Mancuso; Daniela Gallo
Journal:  Oncotarget       Date:  2017-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.